|
|
|
|
| LEADER |
03547nam a22004935i 4500 |
| 001 |
978-94-017-7215-0 |
| 003 |
DE-He213 |
| 005 |
20151111141630.0 |
| 007 |
cr nn 008mamaa |
| 008 |
151103s2015 ne | s |||| 0|eng d |
| 020 |
|
|
|a 9789401772150
|9 978-94-017-7215-0
|
| 024 |
7 |
|
|a 10.1007/978-94-017-7215-0
|2 doi
|
| 040 |
|
|
|d GrThAP
|
| 050 |
|
4 |
|a RC261-271
|
| 072 |
|
7 |
|a MJCL
|2 bicssc
|
| 072 |
|
7 |
|a MED062000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 614.5999
|2 23
|
| 245 |
1 |
0 |
|a Advances in Cancer Biomarkers
|h [electronic resource] :
|b From biochemistry to clinic for a critical revision /
|c edited by Roberto Scatena.
|
| 250 |
|
|
|a 1st ed. 2015.
|
| 264 |
|
1 |
|a Dordrecht :
|b Springer Netherlands :
|b Imprint: Springer,
|c 2015.
|
| 300 |
|
|
|a IX, 372 p. 27 illus., 21 illus. in color.
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 347 |
|
|
|a text file
|b PDF
|2 rda
|
| 490 |
1 |
|
|a Advances in Experimental Medicine and Biology,
|x 0065-2598 ;
|v 867
|
| 505 |
0 |
|
|a Prelims -- I Generality.- II Tumor markers-a critical revision -- Enzymes.- Hormones -- Oncofetal proteins.- Cytokeratins -- Carbohydrate markers -- Blood group antigens.- Genetic markers -- Various protein markers -- III Perspectives.- The role of Circulating tumor Cells as tumor markers -- Index.
|
| 520 |
|
|
|a At present there are a growing number of biomolecules under investigation to understand their potential role as cancer biomarker for diagnostic, prognostic and therapeutic purposes. Intriguingly, the state of art on cancer biomarkers research shows interesting and promising results together to clamorous failures. Also from a clinical point of view, there are contradictory results on routine clinical use of the present cancer biomarkers. Some patients may be simply monitored in their course by a periodic blood sample, but sometimes this monitoring shows dramatic limits. A lot of patients show serious and extensive relapses without significant change in serum concentrations of biomarkers tested. Often the physician who should utilize these biomarker does not entirely know their limits and the total potential applications as well and sometimes this knowledge is influenced by economical and marketing strategies. This limited and “polluted” knowledge may have dramatic consequences for patient. The aim of this book is to diffuse all aspects of cancer biomarkers, from their biochemical peculiarities to all clinical implications by passing through their physiology and pathophysiology. This critical approach towards old and new cancer biomarkers should foster a deepened and useful understanding of the diagnostic and prognostic index of these fundamental parameters of laboratory medicine and in the same time facilitating the research of new and more sensitive-specific signals of the cancer cell proliferation.
|
| 650 |
|
0 |
|a Medicine.
|
| 650 |
|
0 |
|a Cancer research.
|
| 650 |
|
0 |
|a Pharmacology.
|
| 650 |
|
0 |
|a Oncology.
|
| 650 |
1 |
4 |
|a Biomedicine.
|
| 650 |
2 |
4 |
|a Cancer Research.
|
| 650 |
2 |
4 |
|a Oncology.
|
| 650 |
2 |
4 |
|a Pharmacology/Toxicology.
|
| 700 |
1 |
|
|a Scatena, Roberto.
|e editor.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9789401772143
|
| 830 |
|
0 |
|a Advances in Experimental Medicine and Biology,
|x 0065-2598 ;
|v 867
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1007/978-94-017-7215-0
|z Full Text via HEAL-Link
|
| 912 |
|
|
|a ZDB-2-SBL
|
| 950 |
|
|
|a Biomedical and Life Sciences (Springer-11642)
|
